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OBJECTIVE—High-mobility group box-1 (HMGB1) protein is a
nuclear DNA-binding protein released from necrotic cells, induc-
ing inﬂammatory responses and promoting tissue repair and
angiogenesis. Diabetic human and mouse tissues contain lower
levels of HMGB1 than their normoglycemic counterparts. Deﬁ-
cient angiogenesis after ischemia contributes to worse outcomes
of peripheral arterial disease in patients with diabetes. To test the
hypothesis that HMGB1 enhances ischemia-induced angiogene-
sis in diabetes, we administered HMGB1 protein in a mouse hind
limb ischemia model using diabetic mice.
RESEARCH DESIGN AND METHODS—After the induction of
diabetes by streptozotocin, we studied ischemia-induced neovas-
cularization in the ischemic hind limb of normoglycemic, dia-
betic, and HMGB1-treated diabetic mice.
RESULTS—We found that the perfusion recovery was signiﬁ-
cantly attenuated in diabetic mice compared with normoglyce-
mic control mice. Interestingly, HMGB1 protein expression was
lower in the ischemic tissue of diabetic mice than in normogly-
cemic mice. Furthermore, we observed that HMGB1 administra-
tion restored the blood ﬂow recovery and capillary density in the
ischemic muscle of diabetic mice, that this process was associ-
ated with the increased expression of vascular endothelial
growth factor (VEGF), and that HMGB1-induced angiogenesis
was signiﬁcantly reduced by inhibiting VEGF activity.
CONCLUSIONS—The results of this study show that endoge-
nous HMGB1 is crucial for ischemia-induced angiogenesis in
diabetic mice and that HMGB1 protein administration enhances
collateral blood ﬂow in the ischemic hind limbs of diabetic mice
through a VEGF-dependent mechanism. Diabetes 59:1496–
1505, 2010
S
everal long-term complications of diabetes are
characterized by vasculopathy associated with
abnormal angiogenesis. Excessive angiogenesis
plays a role in diabetic retinopathy, nephropathy,
and neuropathy, whereas inhibited angiogenesis contrib-
utes to impaired wound healing and deﬁcient coronary and
peripheral collateral vessel development (1). The in-
creased incidence of morbidity and mortality in diabetes,
from coronary artery disease (CAD) and peripheral artery
disease (PAD), can be because of the reduced ability for
vessel neoformation in the diabetic milieu (2). A diabetes-
induced reduction in collateral vessel formation has been
demonstrated in murine models: hind limb ischemia cre-
ated by femoral artery ligation is associated with the
reduced formation of capillaries and a reduction in blood
ﬂow to the ischemic hind limb in diabetic versus nondia-
betic mice (3).
High-mobility group box-1 (HMGB1) is a nuclear protein
that acts as a cytokine when released into the extracellular
milieu by necrotic and inﬂammatory cells, and is involved
in inﬂammatory responses and tissue repair (4). HMGB1 is
released passively during cellular necrosis by almost all
cells that have a nucleus (5), but is also actively secreted
by immune cells such as monocytes and macrophages (6).
The ﬁrst identiﬁed cellular receptor for this nuclear pro-
tein was the receptor for advanced glycation end products
(RAGE), which mediates the interactions between ad-
vanced glycation end product (AGE)–modiﬁed proteins
and the endothelium and other cell types (7). HMGB1
function is altered in diabetes, and the signaling systems
triggered by this protein are not fully understood. In fact,
diabetic human and mouse skin show lower local levels of
HMGB1 than their normoglycemic counterparts (8). Con-
versely, recent ﬁndings demonstrate that an increased
serum HMGB1 level is associated with CAD in nondiabetic
and type 2 diabetic patients and could contribute to the
progression of atherosclerosis and other cardiovascular
diseases (9). However, despite these apparently conﬂicting
results, this cytokine occupies a central role in mediating
the local and systemic responses to several stimuli and
might have therapeutic relevance. Indeed, vessel-associ-
ated stem cells (mesoangioblasts), injected into the gen-
eral circulation of dystrophic mice, migrate to sites of
tissue damage in response to the HMGB1 signal, by a
nuclear factor-B–dependent mechanism (10). Moreover,
endogenous HMGB1 enhances angiogenesis and restores
cardiac function in a murine model of myocardial infarc-
tion (11), and the exogenous administration of HMGB1
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ventricular function through the regeneration of cardiomyo-
cytes (12). Importantly, HMGB1 is a chemotactic agent in
vitro and in vivo for endothelial precursor cells (EPCs)
(13), and recent ﬁndings demonstrate that HMGB1 admin-
istration signiﬁcantly increases levels of growth factors
including vascular endothelial growth factor (VEGF), ba-
sic ﬁbroblast growth factor, and insulin-like growth fac-
tor-1 released by cultured human cardiac ﬁbroblasts (14).
Given the preexisting data, this study examines whether
HMGB1 plays a role in peripheral ischemia–induced an-
giogenesis in both normoglycemic and diabetic mice.
RESEARCH DESIGN AND METHODS
Mouse model of diabetes. All investigations were approved by the A.
Gemelli University Hospital Institutional Animal Care and Use Committee.
Male C57BL/6J mice (The Jackson Laboratory) aged 8–12 weeks old were
used for experiments. All animals were allowed free access to food and water
throughout the study. Diabetes was induced by administering 50 mg/kg body
wt streptozotocin (STZ; Sigma) in citrate buffer (pH 4.5), intraperitoneally
during the fasting state, consecutively for 5 days, as previously described (15).
Hyperglycemia was veriﬁed, using blood obtained from the tail vein, 2 days
after STZ injections, by an Accu-Check Active glucometer (Roche). We
considered mice to be diabetic when blood glucose was at least 16 mmol/l
(normal 5–8 mmol/l). Overall, 130 mice showed a blood glucose level of at
least 16 mmol/l, both 1 and 2 weeks after the last STZ injection, and were
included in the experimental diabetic group.
Experimental design and groups. To conﬁrm the impaired ischemia-
induced angiogenesis in diabetes, two groups of diabetic and age-matched
C57BL/6J normoglycemic mice (n  10 per group) were used. To investigate
the role of HMGB1 in postischemic angiogenesis in nondiabetic mice, two
more groups of normoglycemic mice (n  10 per group) were studied. For
HMGB1 treatment analysis, 50 diabetic mice were divided into ﬁve groups:
mice treated with 200 ng HMGB1, mice treated with 400 ng HMGB1, mice
treated with 600 ng HMGB1, mice treated with 800 ng HMGB1, and mice
treated with PBS (n  10 per group). To further deﬁne and clarify the
HMGB1-VEGF interaction, 20 more normoglycemic mice and 60 more diabetic
mice were used.
Mouse hind limb ischemia model. Unilateral hind limb ischemia was
induced in both nondiabetic (n  50) and diabetic (2 weeks after the onset of
diabetes, n  130) mice as previously described (16). Brieﬂy, all animals were
anesthetized with an intraperitoneal injection of ketamine (60 mg/kg) and
xylazine (8 mg/kg). The proximal and distal portions of the femoral artery and
the distal portion of the saphenous artery were ligated. The arteries and all
side branches were dissected free and excised. The skin was closed with 5–0
surgical sutures. A laser Doppler perfusion imager system (PeriScan PIM II;
Perimed) was used to measure hind limb blood perfusion before and
immediately after surgery and then at 7-day intervals, until the end of the
study, for a total follow-up of 28 days after surgery. Before imaging, excess
hairs were removed from the limbs using depilatory cream and mice were
placed on a heating plate at 40°C. To avoid the inﬂuence of ambient light and
temperature, results were expressed as the ratio between perfusion in the
right (ischemic) and left (nonischemic) limb.
Exogenous HMGB1 protein administration. In 80 diabetic animals with
unilateral hind limb ischemia, HMGB1 protein (HMGBiotech) was adminis-
tered in a single dose by intramuscular injection, directly into the ischemic
area, at a concentration of 200, 400, 600, and 800 ng per mouse in 0.1 ml of
PBS, respectively (n  10 per group). A separate group of 10 diabetic mice
received an intramuscular injection of 0.1 ml of PBS in the ischemic area. Mice
received HMGB1 or PBS at time 0 (that is, immediately after surgery).
In vivo inhibition of HMGB1 function. The activity of HMGB1 was locally
inhibited in vivo in nondiabetic mice (n  10) by an intramuscular injection of
the HMGB1 inhibitor DNA binding A box (BoxA; HMGBiotech), directly into
the ischemic area 1 h before the induction of the ischemic injury, at a
concentration of 400 ng per mouse in 0.1 ml of PBS, as previously described
(17).
In vivo inhibition of VEGF activity. In this study, we examined whether the
blockade of VEGF signals by sFlt-1, a soluble form of the Flt-1 VEGF receptor
(VEGFR), gene transfer into skeletal muscles can attenuate HMGB1-mediated
vascular neoformation in diabetic mice. Therefore, we used a selective and
speciﬁc inhibitor of VEGF sFlt-1 (18). This isoform is expressed endogenously
by vascular endothelial cells and can inhibit VEGF activity by directly
sequestering VEGF and functioning as a dominant negative inhibitor against
VEGFRs.
Either empty plasmid or sFlt-1 plasmid (100 g/30 l PBS) was injected
into the right femoral muscle of 20 normoglycemic mice, 20 untreated diabetic
mice, and 40 HMGB1-treated diabetic mice (n  10 per group) using a
27-gauge needle 1 day before the induction of ischemic injury (19). To enhance
transgene expression, all plasmid-injected animals received electroporation at
the injection site immediately after injection with an electric pulse generator
as previously described (20–22). To ensure VEGF inhibition, changes in
VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1) phosphorylation were evaluated. A
separate group of 10 HMGB1-treated (800 ng of HMGB1) diabetic mice
received an equal amount of empty plasmid with an intramuscular injection on
the same time schedule.
Histological assays. At 1 and 4 weeks after surgery, mice were killed by an
intraperitoneal injection of an overdose of pentobarbital. The whole limbs
were ﬁxed in methanol overnight. The femora were carefully removed, and the
ischemic thigh muscles were embedded in parafﬁn. All the specimens were
routinely ﬁxed overnight in 4% buffered formalin and embedded in parafﬁn.
Four-micrometer sections of tissue samples were subjected to immunoperox-
idase biotin–avidin reaction using the labeled streptavidin biotin method to
determine CD31, VEGF, and HMGB1 expression. CD45 was used as a marker
for inﬂammatory inﬁltrate. The sections for immunohistochemistry were cut
and mounted on 3-aminopropyltriethoxysilane–coated (Sigma) slides, al-
lowed to dry overnight at 37°C to ensure optimal adhesion, dewaxed,
rehydrated, and treated with 0.3% H2O2 in methanol for 10 min to block
endogenous peroxidase. For antigen retrieval (not necessary for HMGB1 and
VEGF) the sections were microwave treated in 1 mmol/l EDTA at pH 8 (for
CD31) and 10 mmol/l sodium citrate at pH 6 (for CD45) for 10 min, and then
allowed to cool for 20 min. Endogenous biotin was saturated using a biotin
blocking kit (Vector Laboratories). The sections were incubated at room
temperature for 30 min with the following antibodies: puriﬁed rat anti-mouse
CD31 (dilution 1:30; monoclonal [IgG2a]; BD Bioscience), rabbit anti-mouse
HMGB1 (dilution 1:100, polyclonal; Santa Cruz Biotechnology), rabbit anti-
mouse VEGF (dilution 1:100, polyclonal; Santa Cruz Biotechnology), and
rabbit anti-mouse CD45 (dilution 1:50, polyclonal; AbCam). Binding was
visualized using biotinylated secondary antibody (1 h of incubation) and the
streptavidin–biotin peroxidase complex developed with diaminobenzidine.
Finally, slides were counterstained with hematoxylin. Capillary density and
leukocyte inﬁltration were measured by counting six random high-power
(magniﬁcation 200) ﬁelds for a minimum of 200 ﬁbers from each ischemic
and nonischemic limb on an inverted light microscope, and were expressed by
the number of CD31
 or CD45
 cells per square millimeter. Apoptosis was
demonstrated in situ using the Mebstain Apoptosis kit II (Immunotech,
Marseille, France), and the apoptotic index was determined by dividing the
total number of myocytes showing nuclear positivity by the total number of
cells in the ﬁelds examined (23). Necrosis was analyzed semiquantitatively
with a 5 score for severity: 0  none; 1  necrosis of 1–5% of myocytes; 2 
necrosis of 6–25% of myocytes; 3  necrosis of 26–50% of myocytes; and 4 
necrosis 50% of myocytes (24). The area was measured with a National
Institutes of Health image analysis system (ImageJ 1.41). Two operators
extracted the results independently.
Western blotting. Immunoblotting was performed on the homogenates of
muscle tissues. The protein concentration of samples was carefully deter-
mined by the protein assay (Bio-Rad Laboratories). Equal amounts of protein
were subjected to SDS-PAGE electrophoresis using 4–12% gradient gels under
reducing conditions (Bio-Rad Laboratories) and transferred to nitrocellulose
membranes (GE Healthcare). To ensure the equivalent protein loading and
quantitative transfer efﬁciency of proteins, membranes were stained with
Ponceau S before incubating with primary antibodies. Membranes were
incubated with antibodies against HMGB1 (1:500; Santa Cruz Biotechnology),
VEGF (1:500; Santa Cruz Biotechnology), Flt-1 (1:200; Santa Cruz Biotechnol-
ogy), p-Flt-1 (1:200; Santa Cruz Biotechnology), Flk-1 (1:500; Santa Cruz
Biotechnology), and p-Flk-1 (1:500; Santa Cruz Biotechnology). HMGB1,
VEGF, Flt-1, p-Flt-1, Flk-1, and p-Flk-1 expression was normalized using a
mouse monoclonal anti–-tubulin antibody or anti–-actin antibody.
Statistics. Statistical analysis was performed using STATA software (Version
10.0; STATA). Data are expressed as the mean  SEM. Comparison among
groups was carried out using ANOVA followed by Fisher post hoc test.
Repeated-measures ANOVA was used to assess the improvement in perfusion
over time within groups. Signiﬁcance was set at a probability value (P)o f
	0.05.
RESULTS
Impaired angiogenesis in diabetic mice after hind
limb ischemia. Immediately after the femoral artery liga-
tion, blood ﬂow in the ischemic hind limb was equally
reduced in both nondiabetic and diabetic mice (Fig. 1).
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FIG. 1. A: Foot blood ﬂow monitored in vivo by LDPI in control normoglycemic and diabetic mice. Representative evaluation of the ischemic
(right) and nonischemic (left) hind limbs, immediately after, and on days 7, 14, 21, and 28 after surgery. In color-coded images, red indicates
normal perfusion and blue indicates a marked reduction in blood ﬂow in the ischemic hind limb. Blood ﬂow recovery is impaired in diabetic mice
compared with normoglycemic mice. The blood ﬂow of the ischemic hind limb is expressed as the ratio between the perfusion of the ischemic limb
and the uninjured limb. P < 0.05 and P < 0.01 vs. diabetic mice. B: Representative photomicrographs of ischemic muscle sections from control
normoglycemic and diabetic mice stained with antibody directed against VEGF, 7 days after surgery, and against CD31, 28 days after surgery.
Positive staining appears in brown. Magniﬁcation 20. C: Number of vessels per cross section is signiﬁcantly reduced in diabetic mice with
respect to normoglycemic mice. P < 0.05 vs. diabetic mice. D: Representative Western blot of VEGF protein content in the ischemic legs of control
and diabetic mice on postoperative day 7. VEGF expression is reduced in the ischemic tissue of diabetic mice compared with control mice. ns, not
signiﬁcant. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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before, immediately after, and on days 7, 14, 21, and 28
after surgery. Perfusion recovery was signiﬁcantly attenu-
ated in diabetic mice compared with normoglycemic mice
on postoperative days 7, 14, 21, and 28 (Fig. 1A). In
addition, histological analysis revealed that the capillary
density in the ischemic limb was signiﬁcantly increased in
nondiabetic mice, whereas no such increase was noted in
diabetic mice at 4 weeks after the hind limb ischemia (Fig.
1B and C). Furthermore, immunostaining and immunoblot
analyses showed increased VEGF expression in the isch-
emic tissue of normoglycemic mice compared with dia-
betic mice on postoperative day 7 (Fig. 1B and D). In
agreement with previous data (3), these ﬁndings conﬁrm
the relative inability of diabetes to mount a robust angio-
genic response to ischemia after arterial occlusion (25).
HMGB1 in normoglycemic and diabetic ischemic hind
limbs. To test whether HMGB1 is involved in impaired
ischemia-induced angiogenesis, we ﬁrst evaluated HMGB1
expression in both nondiabetic and diabetic mice by immu-
nohistochemical and Western blot analysis 7 days after
ischemic injury. In relation to the expression of HMGB1 in
uninjured tissues, there was reduced nuclear positivity in
diabetic hind limbs compared with normoglycemic mice
(Fig. 2A). Interestingly, although operated normoglycemic
mice showed strong expression of HMGB1 in inﬁltrating
leukocytes (Fig. 2A), HMGB1-positive cells were reduced in
ischemic hind limbs of diabetic mice compared with nondi-
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ported the evidence that HMGB1 protein expression was
reduced in the ischemic tissue of diabetic mice (Fig. 2B). To
test whether observed HMGB1 changes were dependent on
either different tissue damage between the two groups or an
altered regulation per se, we analyzed leukocyte inﬁltration,
apoptosis, and necrosis and noted there were no differences
between control and diabetic mice according to all three
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the observed difference in HMGB1 expression does not
depend on a different response to ischemic injury between
the two groups.
Inhibition of endogenous HMGB1 impairs ischemia-
induced angiogenesis in normoglycemic mice. To fur-
ther investigate the role of HMGB1 in postischemic
angiogenesis in normoglycemic mice, we tested the effect
of HMGB1 blockade in normoglycemic mice using the
HMGB1 BoxA, a truncated form of the protein that acts as
a competitive antagonist by inhibiting HMGB1 binding to
its receptor RAGE (26), directly in the ischemic area. LDPI
showed that perfusion recovery was signiﬁcantly attenu-
ated on postoperative days 7, 14, 21, and 28 in BoxA-
treated mice compared with vehicle-treated mice (Fig.
3A). Consistent with the measurement of LDPI, anti-CD31
immunostaining at day 28 revealed that angiogenesis in the
ischemic hind limb was impaired in mice treated with
BoxA (Fig. 3B and C). To our knowledge, this is the ﬁrst
demonstration that HMGB1 plays an important role in
ischemia-induced angiogenesis.
Exogenous HMGB1 administration enhances blood
ﬂow recovery in diabetic mice. The lower HMGB1 level
in the ischemic hind limbs of diabetic mice and the
impaired ischemia-induced angiogenesis observed in nor-
moglycemic mice treated with competitive HMGB1-antag-
onist suggested that HMGB1 might have a function in
postischemic vessel neoformation in diabetic mice. Thus,
we administered exogenous HMGB1 protein directly into
the ischemic area of diabetic mice, by intramuscular
injection, at a concentration of 200, 400, 600, and 800 ng
per mouse, respectively (n  10 per group). Control
diabetic mice (n  10) received an equal amount of PBS
on the same time schedule. In response to HMGB1 admin-
istration, perfusion recovery was signiﬁcantly improved
on postoperative days 7, 14, 21, and 28 compared with
mice treated with PBS (Fig. 4). In accordance with LDPI
data, HMGB1 administration signiﬁcantly restored the
number of detectable capillaries in the ischemic legs of
diabetic mice to a normal level 28 days after surgery (Fig.
5A and B). Moreover, we evaluated whether VEGF is
expressed in association with HMGB1-induced neovascu-
larization. Immunostaining (data not shown) and Western
blot analyses demonstrated that VEGF protein levels were
signiﬁcantly increased in the ischemic hind limbs of dia-
betic mice treated with 200, 400, 600, and 800 ng of HMGB1
compared with mice treated with PBS (Fig. 5C). These
ﬁndings ﬁrst demonstrate that exogenous HMGB1 admin-
istration enhances ischemia-induced angiogenesis in dia-
betic mice and that this angiogenic response occurs in
association with VEGF production.
HMGB1 promotes angiogenesis in diabetic mice
through a VEGF-dependent mechanism. Following the
observation that HMGB1-induced postischemic neoangio-
genesis in diabetic mice occurs in association with VEGF
generation, we tested the hypothesis that the angiogenic
properties of HMGB1 might depend on VEGF activity.
Therefore, we suppressed VEGF activity in vivo and
evaluated whether HMGB1 was still able to improve
postischemic angiogenesis in diabetic mice. The in vivo
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plasmid, which suppresses VEGF activity both by seques-
tering VEGF and functioning as a dominant-negative inhib-
itor of VEGFRs (27). Changes in VEGFR (Flt-1 and Flk-1)
phosphorylation were evaluated (Fig. 6A), conﬁrming the
inhibition of the VEGF pathway. Normoglycemic and
diabetic mice transfected with the empty vector or sFlt-1
plasmid were used as controls (Fig. 6B). A signiﬁcant
reduction in HMGB1-induced neoangiogenesis was ob-
served when VEGF activity was suppressed (Fig. 6C).
LDPI demonstrated that the inhibition of VEGF activity
resulted in a signiﬁcant reduction of HMGB1-induced
blood ﬂow recovery on postoperative days 7, 14, 21, and
28. Consistent with these LDPI data, HMGB1 administra-
tion did not restore the number of detectable capillaries in
the ischemic leg of diabetic mice 28 days after surgery,
when VEGF activity was inhibited (Fig. 6C). These ﬁndings
demonstrate that exogenous HMGB1 administration en-
hances ischemia-induced angiogenesis in diabetic mice via
a VEGF-dependent mechanism.
DISCUSSION
The impaired angiogenic response to ischemia after arte-
rial occlusion might contribute to the poor clinical out-
comes observed in diabetic patients with CAD or PAD
(25,28). Various hypotheses have been postulated to ex-
plain the impaired postischemic angiogenic response in
diabetes, such as the vascular dysfunction characterized
by both endothelial and vascular smooth muscle cell
impairments (29), the decreased release or defective func-
tion of EPCs from the bone marrow (30), or the presence
of maladaptive dysregulation of vascular growth factor
pathways (31). Although a number of factors are likely to
contribute to reduced angiogenesis in diabetes, the results
of our study are the ﬁrst to describe alterations in the
HMGB1 system as a potential contributor to this process.
Endothelial cells, which form the inner lining of blood
vessels, express RAGE, the cell surface receptor that binds
AGEs (32). One way in which AGEs might accelerate the
development of macrovascular disease in diabetes is the
induction of endothelial cell surface adhesion molecules
resulting from the interaction of AGEs with their receptors
RAGE (33), a phenomenon that might be a marker for the
amount and progression of vascular disease in diabetes
(34). But there is another important signaling system
related to RAGE, that is, the HMGB1 pathway, involving a
new cytokine that is released from certain cells in re-
sponse to other cytokines and from necrotic cells (35).
Upon binding to RAGE, HMGB1 activates key cell signal-
ing pathways, for example, mitogen-activated protein ki-
nases and nuclear factor-B (10). Through its secretion by
activated macrophages HMGB1 again activates macro-
phages, resulting in the secretion of angiogenic factors
such as VEGF, tumor necrosis factor-, and interleukin-8
(36). Furthermore, several reports have suggested that
HMGB1 plays a key role in angiogenesis through multiple
mechanisms, including the upregulation of proangiogenic
factors, promoting the homing of EPCs to ischemic tissues
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Other authors have demonstrated that the RAGE blockade
inhibits HMGB1-induced neovascularization and endothe-
lial cell proliferation in vitro (38) and that exogenous
HMGB1 administration enhances angiogenesis and re-
stores cardiac function in vivo (12). With regard to diabe-
tes, a recent study showed that HMGB1 is underexpressed
in the skin of diabetic mice and ﬁbroblasts of patients
affected by diabetes, that endogenous HMGB1 is crucial
for skin tissue repair, that the reduced levels of HMGB1 in
diabetic skin might impair wound healing, and that the
exogenous topical administration of HMGB1 is able to
correct this defect (8).
In our current study, we found that mice with diabetes
have impaired perfusion recovery after femoral artery
ligation and excision, in accordance with previous reports
(39), and the preexisting evidence prompted us to inves-
tigate the role of HMGB1 in impaired ischemia-induced
angiogenesis in diabetes. We observed that HMGB1 ex-
pression is reduced in the ischemic tissues of diabetic
mice compared with normoglycemic mice. To our knowl-
edge, this is the ﬁrst demonstration that HMGB1 content is
lower in the ischemic hind limb of diabetic mice. These
ﬁndings are consistent with a previous report that showed
that endogenous HMGB1 is reduced in other injured
diabetic tissues (8). Thus, we further examined whether
HMGB1 is crucial for postischemic angiogenesis. To test
our hypothesis, we ﬁrst inhibited the HMGB1 pathway
using BoxA, which acts by inhibiting HMGB1 binding to its
receptor RAGE, and we observed that when the local
activity of this cytokine is reduced, ischemia-induced
neovascularization is impaired in normoglycemic mice.
This is another important result of our study because, in
accordance with other authors, it seems reasonable to
assume that HMGB1, through binding RAGE, can also act
as an angiogenic switch molecule (37). Accordingly, we
suggested that reduced HMGB1 in diabetic ischemic hind
limbs might account, at least in part, for the impaired
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with this hypothesis, we noted that local HMGB1 admin-
istration enhanced postischemic neoangiogenesis in dia-
betic mice. These ﬁndings were evident 7 days after
ischemia, when perfusion recovery and the inﬂammatory
response were comparable in the ischemic tissue of con-
trol and diabetic mice, further suggesting that these
changes in the HMGB1 system play a causative role in the
impaired recovery seen at later time points. These data
represent the third relevant discovery of our work because
they indicate that the local administration of HMGB1
could be an attractive approach for treating PAD in
patients with diabetes. There are several mechanisms by
which HMGB1 can promote this process, but we focused
our attention on the VEGF pathway. In this regard, we
initially found that VEGF protein levels are signiﬁcantly
increased in the ischemic hind limbs of diabetic mice
treated with HMGB1 relative to untreated mice. Thus, we
tested the hypothesis that the angiogenic properties of
HMGB1 might depend on VEGF activity. Therefore, we
suppressed VEGF activity and found a substantial reduc-
tion of HMGB1-induced neoangiogenesis when VEGF ac-
tivity is suppressed. These ﬁndings demonstrate that
exogenous HMGB1 administration enhances ischemia-in-
duced angiogenesis in diabetic mice via a VEGF-depen-
dent mechanism.
Our observations are consistent with several studies
that have shown that HMGB1 has the properties of an
angiogenic cytokine in promoting endothelial cell sprout-
ing and migration under hypoxic and necrotic conditions
(37). Furthermore, studies on the transcriptional proﬁles
of angiogenic endothelial cells have revealed HMGB1 as a
potentially angiogenic factor (40). By contrast, other data
have suggested a potential role for HMGB1 in atheroscle-
rosis (41), demonstrating enhanced HMGB1 expression in
atherosclerotic lesions compared with normal arteries.
These considerations and our original results indicate that
the HMGB1/RAGE system in cardiovascular diseases acts
as a double-edged sword in a scenario, such as tissue
ischemia, in which autocrine, paracrine, or the combined
effects of the HMGB1/RAGE system on different cell types
might lead either to injury or repair phenomena. However,
an emerging function of HMGB1 in tissue repair is cur-
rently being actively investigated. For example, HMGB1
plays an important role in axonal regeneration (42) and
myogenesis (43) in a RAGE-dependent manner. Further-
more, HMGB1 is implicated in stem cell homing and
development (4,44). In fact, low doses of HMGB1 are
capable of activating stem cells, which is expected to be
useful in tissue regeneration, as demonstrated for cardiac
(44) and neural (45) repair.
In conclusion, we have demonstrated that a disturbed
tolerance against severe limb ischemia under hyperglyce-
mia is, at least in part, attributable to the disturbance of
the HMGB1 pathway, and that the local administration of
the HMGB1 protein is sufﬁcient to improve neoangiogen-
esis caused by limb ischemia in diabetic mice. We have
also shown that this angiogenic response is dependent on
VEGF. Therefore, the HMGB1 signaling system could be
an attractive molecular target for treating PAD in patients
with diabetic vascular complications.
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